DexCom, Inc. Financials

Market Capitalization $34.26 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	53.15
Forward PE	43.20
Price to Sales TTM	$8.66
Price to Book MRQ	$17.31
Enterprise to Revenue	8.69
Enterprise to EBITDA	40.88

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	17.22%
Operating Margin	15.29%
Return on Assets TTM	6.06%
Return on Equity TTM	32.06%

Income Statement

Revenue TTM	$3,953,999,872
Revenue per Share TTM	$10.09
Quarterly Revenue Growth	2.00%
Gross Profit TTM	$2,439,000,064
EBITDA	$975,300,000
Net Income to Common TTM	$680,800,000
Diluted EPS TTM	$1.65
Quarterly Earnings Growth YoY	11.50%

Balance Sheet

Total Cash MRQ	$2,492,300,032
Total Cash per Share MRQ	$6.38
Total Debt MRQ	$
Total Debt to Equity MRQ	130.94
Current Ratio MRQ	2.46
Book Value per Share MRQ	$5.07

Cash Flow

Operating Cash Flow TTM	$821,699,968
Levered Free Cash Flow TTM	$353,224,992

DXCM Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	390,595,008
Float Shares	387,517,498
Avg 10 Volume	4,390,570
Avg 30 Volume	None
Shares Short	8,796,878
Short Ratio	2.73
Short % of Shares	2.55%
% Held by Insiders	0.31%
% Held by Institutions	97.03%

Stock Price Summary

Beta	1.17
Fifty Two Week Low	$62.34
Fifty Two Week High	$142.00
Fifty Two Week Change	-40.00%
Day 50 MA	$78.47
Day 200 MA	$92.10

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2022-06-13